Cardioprotective Effects of a Selective c-Jun N-terminal Kinase Inhibitor in a Rat Model of Myocardial Infarction

被引:6
|
作者
Plotnikov, Mark B. [1 ,2 ]
Chernysheva, Galina A. [1 ]
Smol'yakova, Vera I. [1 ]
Aliev, Oleg I. [1 ]
Fomina, Tatyana I. [1 ]
Sandrikina, Lyubov A. [1 ]
Sukhodolo, Irina V. [3 ]
Ivanova, Vera V. [3 ]
Osipenko, Anton N. [4 ]
Anfinogenova, Nina D. [5 ]
Khlebnikov, Andrei I. [6 ]
Atochin, Dmitriy N. [6 ,7 ]
Schepetkin, Igor A. [8 ]
Quinn, Mark T. [8 ]
机构
[1] Russian Acad Sci, Goldberg Res Inst Pharmacol & Regenerat Med, Tomsk Natl Res Med Ctr, Dept Pharmacol, Tomsk 634028, Russia
[2] Natl Res Tomsk State Univ, Fac Radiophys, Tomsk 634050, Russia
[3] Siberian State Med Univ, Dept Morphol & Gen Pathol, Tomsk 634050, Russia
[4] Siberian State Med Univ, Dept Pharmacol, Tomsk 634050, Russia
[5] Russian Acad Sci, Tomsk Natl Res Med Ctr, Cardiol Res Inst, Tomsk 634012, Russia
[6] Tomsk Polytech Univ, Kizhner Res Ctr, Tomsk 634050, Russia
[7] Harvard Med Sch, Massachusetts Gen Hosp, Cardiovasc Res Ctr, Cardiol Div, Charlestown, MA 02115 USA
[8] Montana State Univ, Dept Microbiol & Cell Biol, Bozeman, MT 59717 USA
基金
美国国家卫生研究院;
关键词
cardioprotective activity; c-Jun N-terminal kinase inhibitor; 11H-indeno[1; 2-b]quinoxalin-11-one oxime; heart failure; infarct size; myocardial infarction; ischemia; reperfusion; ISCHEMIA-REPERFUSION INJURY; ACTIVATED PROTEIN-KINASE; HEART-FAILURE; CARDIOMYOCYTE APOPTOSIS; ISCHEMIA/REPERFUSION INJURY; NH2-TERMINAL KINASE; SIGNALING PATHWAYS; JNK; PROTECTION; STRESS;
D O I
10.3390/biomedicines11030714
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Activation of c-Jun N-terminal kinases (JNKs) is involved in myocardial injury, left ventricular remodeling (LV), and heart failure (HF) after myocardial infarction (MI). The aim of this research was to evaluate the effects of a selective JNK inhibitor, 11H-indeno [1,2-b]quinoxalin-11-one oxime (IQ-1), on myocardial injury and acute myocardial ischemia/reperfusion (I/R) in adult male Wistar rats. Intraperitoneal administration of IQ-1 (25 mg/kg daily for 5 days) resulted in a significant decrease in myocardial infarct size on day 5 after MI. On day 60 after MI, a significant (2.6-fold) decrease in LV scar size, a 2.2-fold decrease in the size of the LV cavity, a 2.9-fold decrease in the area of mature connective tissue, and a 1.7-fold decrease in connective tissue in the interventricular septum were observed compared with the control group. The improved contractile function of the heart resulted in a significant (33%) increase in stroke size, a 40% increase in cardiac output, a 12% increase in LV systolic pressure, a 28% increase in the LV maximum rate of pressure rise, a 45% increase in the LV maximum rate of pressure drop, a 29% increase in the contractility index, a 14% increase in aortic pressure, a 2.7-fold decrease in LV end-diastolic pressure, and a 4.2-fold decrease in LV minimum pressure. We conclude that IQ-1 has cardioprotective activity and reduces the severity of HF after MI.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] The c-Jun N-terminal kinase inhibitor SP600125 inhibits human cytomegalovirus replication
    Zhang, Huiping
    Niu, Xiaofeng
    Qian, Zhikang
    Qian, Jihong
    Xuan, Baoqin
    JOURNAL OF MEDICAL VIROLOGY, 2015, 87 (12) : 2135 - 2144
  • [22] c-Jun N-terminal kinase regulates apoptosis in endometrial cancer cells
    Reno, Elaine M.
    Haughian, James M.
    Jackson, Twila A.
    Thorne, Alicia M.
    Bradford, Andrew P.
    APOPTOSIS, 2009, 14 (06) : 809 - 820
  • [23] Hemostimulating Effects of c-Jun N-Terminal Kinase (JNK) Inhibitor during Cytostatic Myelosuppression and Mechanisms of Their Development
    G. N. Zyuz’kov
    V. V. Zhdanov
    L. A. Miroshnichenko
    E. V. Simanina
    T. Yu. Polyakova
    L. A. Stavrova
    V. I. Agafonov
    M. Yu. Minakova
    M. G. Danilets
    A. A. Ligacheva
    Bulletin of Experimental Biology and Medicine, 2020, 169 : 332 - 337
  • [24] Hemostimulating Effects of c-Jun N-Terminal Kinase (JNK) Inhibitor during Cytostatic Myelosuppression and Mechanisms of Their Development
    Zyuz'kov, G. N.
    Zhdanov, V. V.
    Miroshnichenko, L. A.
    Simanina, E. V.
    Polyakova, T. Yu.
    Stavrova, L. A.
    Agafonov, V. I.
    Minakova, M. Yu.
    Danilets, M. G.
    Ligacheva, A. A.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2020, 169 (03) : 332 - 337
  • [25] Discovery of a selective and potent inhibitor of c-Jun N-terminal kinase 1 with anti-pulmonary fibrosis effect
    Ren, Shuhua
    Liu, Fengling
    Chi, Man
    Liu, Jinfeng
    Huang, Yi
    Huang, Weiwei
    Gu, Wenjing
    Yuan, Yaxia
    Hou, Shurong
    Chen, Xiabin
    Ma, Lei
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2025, 116
  • [26] Antihypertensive activity of a new c-Jun N-terminal kinase inhibitor in spontaneously hypertensive rats
    Plotnikov, Mark B.
    Aliev, Oleg, I
    Shamanaev, Aleksandr Y.
    Sidekhmenova, Anastasia, V
    Anishchenko, Anna M.
    Fomina, Tatiana, I
    Rydchenko, Victoria S.
    Khlebnikov, Andrei, I
    Anfinogenova, Yana J.
    Schepetkin, Igor A.
    Atochin, Dmitriy N.
    HYPERTENSION RESEARCH, 2020, 43 (10) : 1068 - 1078
  • [27] Tolerance to the antinociceptive effects of chronic morphine requires c-Jun N-terminal kinase
    Marcus, David J.
    Zee, Michael
    Hughes, Alex
    Yuill, Matthew B.
    Hohmann, Andrea G.
    Mackie, Ken
    Guindon, Josee
    Morgan, Daniel J.
    MOLECULAR PAIN, 2015, 11
  • [28] Stressor-Like Effects of c-Jun N-Terminal Kinase (JNK) Inhibition
    Clarke, Melanie
    Pentz, Rowan
    Bobyn, Jessica
    Hayley, Shawn
    PLOS ONE, 2012, 7 (08):
  • [29] c-Jun N-terminal kinase is involved in motility of endothelial cell
    Shin, EY
    Kim, SY
    Kim, EG
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2001, 33 (04) : 276 - 283
  • [30] c-Jun N-terminal kinase is involved in motility of endothelial cell
    Eun-Young Shin
    Seok-Yong Kim
    Eung-Gook Kim
    Experimental & Molecular Medicine, 2001, 33 : 276 - 283